| Name | Bebtelovimab |
|---|
| Description | Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy[1][2]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |